Experimental study on antitumor effect of monoclonal anti-idiotypic antibody-DNR conjugate to leukemia
Abstract
In this experiment, the Dextran-T40 (Dex-T40) served as intermidiate carrier, conjugated SM6 monoclonal anti-idiotypic antibody (anti-Id-McAb) against B lymphocytic leukemia cells and chemotherapeutical drug daunorubicin (DNR) to form SM6: Dex: DNR immunoconjugate. The activity of anti-Id-McAb and DNR of the immunoconjugate and their extent of the substitution were measured, and the antitumor activity of SM6: Dex: DNR was assayedin vitro. The results demonstrated that using Dex-T40 to prepare immunoconjugate could get a higher extent of substitution of McAb and DNR and maintain the activity of McAb and drug well. The results of cytotoxic assayin vitro suggested that the immunoconjugate SM6: Dex: DNR possess a specific cytotoxic effect to target tumor cells.
Related Papers
- → chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts(2007)28 cited
- [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].(2003)
- → Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice(1992)7 cited
- A phase I study: Immunotoxin targeting the epithelial glycoprotein 2 (ESA/Ep-CAM) in cancer patients(2007)
- Monoclonal antibody immunoconjugates in the diagnosis and treatment of advanced melanoma.(1992)